Nanjing Baixin Yu Pharmaceutical

Nanjing Baixinyu Pharmaceutical is a Chinese biotechnology company focused on the research and development of innovative small molecule therapeutics for metabolic and endocrine disorders. The company specializes in developing oral agonists for key metabolic receptors, including GLP-1, GCG, and GIP, aiming to provide more convenient treatment options for chronic conditions such as type 2 diabetes and obesity. Based in Nanjing, the firm leverages its expertise in medicinal chemistry to advance a pipeline of next-generation metabolic regulators. Their lead programs are currently in the pre-clinical and early development stages, targeting high-prevalence metabolic indications.